@article {Braybcr-2017-223352, author = {Jonathan James Hyett Bray and Chiara Bucciarelli-Ducci and Graham Stuart}, title = {Implantable cardioverter defibrillators in the context of hypertrophic cardiomyopathy: a lesson in patient autonomy}, volume = {2018}, elocation-id = {bcr-2017-223352}, year = {2018}, doi = {10.1136/bcr-2017-223352}, publisher = {BMJ Publishing Group}, abstract = {Hypertrophiccardiomyopathy (HCM) is common, whereas the decision not to have an implantable cardioverterdefibrillator (ICD) when probably falling into a {\textquoteleft}high-risk{\textquoteright} category is not. A solicitor aged 45 years attended the inherited cardiac conditions clinic for review of her HCM and discussion about ICD implantation for primary prevention of sudden cardiac death (SCD). Despite a predicted 7\% risk of SCD within the next 5 years, according to the European Society of Cardiology endorsed HCM Risk-SCD risk stratification tool, the patient opted against implantation of an ICD and comprehensively justifies her decision. This report discusses ethical aspects of a consultation offering ICD protection against SCD in the context of HCM and emphasises the clinicians{\textquoteright} role in respecting patient autonomy.}, URL = {https://casereports.bmj.com/content/2018/bcr-2017-223352}, eprint = {https://casereports.bmj.com/content/2018/bcr-2017-223352.full.pdf}, journal = {Case Reports} }